Welcome to our dedicated page for Medexus Pharmace news (Ticker: MEDXF), a resource for investors and traders seeking the latest updates and insights on Medexus Pharmace stock.
Medexus Pharms Inc (MEDXF), referred to in its disclosures as Medexus Pharmaceuticals, generates a steady flow of news related to its specialty pharmaceutical business in North America. Investors following MEDXF news can see updates on hematology and hematology-oncology products, as well as allergy, dermatology, and rheumatology therapies that form the company’s core portfolio.
Many Medexus news releases focus on GRAFAPEX (treosulfan) for Injection, an alkylating agent used as part of a preparative regimen for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndrome. The company reports on FDA approval, Orphan Drug Designation, US commercial launch timing, and key reimbursement milestones such as CMS New Technology Add-On Payment (NTAP) approval, transitional pass-through status, and assignment of a permanent HCPCS Level II "J code". These items provide insight into how Medexus is building its hematology-oncology franchise in the United States.
MEDXF news also covers quarterly and annual financial results, including net revenue, net income, Adjusted EBITDA, and product-level performance for GRAFAPEX, Trecondyv, IXINITY, Rupall, Rasuvo, Metoject, and Gleolan. The company uses these releases to discuss unit demand trends, the impact of generic competition on products such as Rupall, and portfolio dynamics across the United States and Canada.
Additional news topics include financing and capital allocation decisions, such as new senior secured credit facilities with National Bank of Canada, repayment of prior credit agreements, and the launch or renewal of a normal course issuer bid (NCIB) for Medexus common shares on the Toronto Stock Exchange. Governance-related items, including annual meetings of shareholders, director elections, and auditor appointments, are also reported.
For anyone tracking MEDXF, this news stream offers detailed information on product launches, regulatory and reimbursement milestones, financial performance, credit arrangements, and share repurchase activity. Bookmarking the Medexus news feed on Stock Titan can help investors and researchers follow how the company’s North American specialty pharmaceutical platform evolves over time.
Medexus Pharmaceuticals plans to host a conference call at 8:00 AM ET on March 2, 2021, to discuss its financial results for the third quarter of fiscal 2021, which ended on December 31, 2020. The company will file its financial statements on March 1, 2021. Investors can access the call via phone or through a webcast. Medexus focuses on orphan and rare diseases, providing products like Rasuvo™ and IXINITY® for conditions including rheumatoid arthritis and Hemophilia B. For further insights, the company promotes its commitment to quality, innovation, and customer service.
Medexus Pharmaceuticals announced its upcoming presentation at the virtual Winter Wonderland Conference, hosted by The MicroCap Rodeo, from February 16-19, 2021. CEO Ken d’Entremont and CFO Roland Boivin will present on February 17 at 9:30 AM ET, with the session available for live streaming and replay. Medexus is recognized for its innovative products in treating rare diseases, specializing in auto-immune diseases, hematology, and allergies. Key products include Rasuvo™, Metoject®, IXINITY®, and Rupall®.
Medexus Pharmaceuticals (OTCQX: MEDXF) will present at the LD 500 Investor conference virtually from September 1-4, 2020. CEO Ken d'Entremont and CFO Roland Boivin are scheduled to speak on September 1 at 11:40 a.m. ET, with a live webcast available.
Attendees can schedule one-on-one video meetings and register for the event online. Medexus specializes in healthcare products for auto-immune diseases, hematology, and allergy treatments, with notable products including Rasuvo™, IXINITY®, and Rupall®.